Winston Intangible Assets from 2010 to 2026

WPHM Stock  USD 0.0003  0.00  0.00%   
Winston Pharmaceuticals Intangible Assets yearly trend continues to be very stable with very little volatility. Intangible Assets are likely to grow to about 18 K this year. Intangible Assets is non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value. View All Fundamentals
 
Intangible Assets  
First Reported
2010-12-31
Previous Quarter
15.7 K
Current Value
18 K
Quarterly Volatility
2.5 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Winston Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Winston Pharmaceuticals' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 0.0 or Selling General Administrative of 1.5 M, as well as many indicators such as Price To Sales Ratio of 8.02, Dividend Yield of 0.0 or PTB Ratio of 10.66. Winston financial statements analysis is a perfect complement when working with Winston Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Winston Stock
Check out the analysis of Winston Pharmaceuticals Correlation against competitors.
To learn how to invest in Winston Stock, please use our How to Invest in Winston Pharmaceuticals guide.

Latest Winston Pharmaceuticals' Intangible Assets Growth Pattern

Below is the plot of the Intangible Assets of Winston Pharmaceuticals over the last few years. It is non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value. Winston Pharmaceuticals' Intangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Winston Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Intangible Assets10 Years Trend
Slightly volatile
   Intangible Assets   
       Timeline  

Winston Intangible Assets Regression Statistics

Arithmetic Mean17,980
Geometric Mean17,854
Coefficient Of Variation13.93
Mean Deviation1,132
Median17,455
Standard Deviation2,504
Sample Variance6.3M
Range11.8K
R-Value(0.44)
Mean Square Error5.4M
R-Squared0.19
Significance0.08
Slope(215.95)
Total Sum of Squares100.3M

Winston Intangible Assets History

202618 K
202515.7 K
201117.5 K
201027.5 K

About Winston Pharmaceuticals Financial Statements

Winston Pharmaceuticals investors utilize fundamental indicators, such as Intangible Assets, to predict how Winston Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Intangible Assets15.7 K18 K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Winston Pharmaceuticals is a strong investment it is important to analyze Winston Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Winston Pharmaceuticals' future performance. For an informed investment choice regarding Winston Stock, refer to the following important reports:
Check out the analysis of Winston Pharmaceuticals Correlation against competitors.
To learn how to invest in Winston Stock, please use our How to Invest in Winston Pharmaceuticals guide.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Will Drug Manufacturers - Specialty & Generic sector continue expanding? Could Winston diversify its offerings? Factors like these will boost the valuation of Winston Pharmaceuticals. Anticipated expansion of Winston directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Winston Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Revenue Per Share
0.021
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.59)
Return On Equity
(2.05)
The market value of Winston Pharmaceuticals is measured differently than its book value, which is the value of Winston that is recorded on the company's balance sheet. Investors also form their own opinion of Winston Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Winston Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Winston Pharmaceuticals' market value can be influenced by many factors that don't directly affect Winston Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Winston Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Winston Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Winston Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.